Healthcare provider profile · identity verified

Alkesh C Amin, MD

Allopathic & Osteopathic Physicians|Internal Medicine · LAKE JACKSON, TX · NPI 1215977145

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alkesh C Amin, MD received $21.58 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 443 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$21.58

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$21.58	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$21.58	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$21.58	1	2025
Source payment records 2025-05-03 · Lilly USA, LLC · $21.58 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	178	50
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	443	78
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	158	22

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	1638	460
Atorvastatin Calcium	Atorvastatin Calcium	1561	446
Levothyroxine Sodium	Levothyroxine Sodium	1279	304
Rosuvastatin Calcium	Rosuvastatin Calcium	845	235
Metoprolol Succinate	Metoprolol Succinate	632	184
Losartan Potassium	Losartan Potassium	617	172
Gabapentin	Gabapentin	549	150
Carvedilol	Carvedilol	537	150
Famotidine	Famotidine	518	149
Metoprolol Tartrate	Metoprolol Tartrate	518	143
Mounjaro	Tirzepatide	443	78
Omeprazole	Omeprazole	415	119
Lisinopril	Lisinopril	377	110
Furosemide	Furosemide	350	108
Escitalopram Oxalate	Escitalopram Oxalate	325	87
Alprazolam	Alprazolam	301	52
Simvastatin	Simvastatin	301	80
Pantoprazole Sodium	Pantoprazole Sodium	294	87
Tamsulosin Hcl	Tamsulosin Hcl	291	87
Hydralazine Hcl	Hydralazine Hcl	287	74
Trazodone Hcl	Trazodone Hcl	268	78
Eliquis	Apixaban	261	60
Hydrochlorothiazide	Hydrochlorothiazide	253	80
Metformin Hcl	Metformin Hcl	235	72
Olmesartan Medoxomil	Olmesartan Medoxomil	227	58
Sertraline Hcl	Sertraline Hcl	212	53
Ezetimibe	Ezetimibe	211	58
Pravastatin Sodium	Pravastatin Sodium	186	53
Montelukast Sodium	Montelukast Sodium	185	52
Potassium Chloride	Potassium Chloride	184	56
Duloxetine Hcl	Duloxetine Hcl	183	39
Jardiance	Empagliflozin	178	50
Allopurinol	Allopurinol	171	46
Meloxicam	Meloxicam	169	81
Farxiga	Dapagliflozin Propanediol	168	37
Trulicity	Dulaglutide	158	22
Prednisone	Prednisone	156	118
Clopidogrel	Clopidogrel Bisulfate	144	46
Zolpidem Tartrate	Zolpidem Tartrate	144	24
Paroxetine Hcl	Paroxetine Hcl	142	24
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	140	109
Ciprofloxacin Hcl	Ciprofloxacin Hcl	140	123
Doxazosin Mesylate	Doxazosin Mesylate	140	33
Ropinirole Hcl	Ropinirole Hcl	133	36
Fluticasone Propionate	Fluticasone Propionate	131	56
Ozempic	Semaglutide	131	24
Amoxicillin	Amoxicillin	129	117
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	121	30
Finasteride	Finasteride	116	31
Amitriptyline Hcl	Amitriptyline Hcl	110	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	109	33
Gemfibrozil	Gemfibrozil	108	32
Valsartan	Valsartan	108	36
Clonidine Hcl	Clonidine Hcl	103	31
Xarelto	Rivaroxaban	102	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	101	28
Tramadol Hcl	Tramadol Hcl	97	22
Quetiapine Fumarate	Quetiapine Fumarate	96	16
Nystatin	Nystatin	91	30
Mirtazapine	Mirtazapine	89	26
Ibandronate Sodium	Ibandronate Sodium	88	30
Albuterol Sulfate Hfa	Albuterol Sulfate	83	36
Amiodarone Hcl	Amiodarone Hcl	82	17
Celecoxib	Celecoxib	80	16
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	80	21
Oxybutynin Chloride Er	Oxybutynin Chloride	79	21
Januvia	Sitagliptin Phosphate	78	25
Glimepiride	Glimepiride	77	29
Lorazepam	Lorazepam	75	11
Pioglitazone Hcl	Pioglitazone Hcl	75	19
Synthroid	Levothyroxine Sodium	73	20
Metformin Hcl Er	Metformin Hcl	72	22
Levofloxacin	Levofloxacin	70	53
Azithromycin	Azithromycin	69	57
Tradjenta	Linagliptin	68	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	68	17
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	66	55
Fenofibrate	Fenofibrate Nanocrystallized	64	20
Paxlovid	Nirmatrelvir/Ritonavir	63	61
Alendronate Sodium	Alendronate Sodium	61	21
Citalopram Hbr	Citalopram Hydrobromide	60	14
Nifedipine Er	Nifedipine	60	14
Atenolol	Atenolol	59	15
Breo Ellipta	Fluticasone/Vilanterol	58	11
Doxycycline Monohydrate	Doxycycline Monohydrate	56	43
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	55	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	55	46
Sotalol	Sotalol Hcl	53	13
Spironolactone	Spironolactone	49	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	49	12
Propranolol Hcl	Propranolol Hcl	48	13
Ondansetron Hcl	Ondansetron Hcl	43	24
Buspirone Hcl	Buspirone Hcl	41	13
Eszopiclone	Eszopiclone	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	41	suppressed
Colchicine	Colchicine	40	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	40	11
Wixela Inhub	Fluticasone Propion/Salmeterol	40	suppressed
Bupropion Hcl Sr	Bupropion Hcl	39	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	39	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	39	suppressed
Metolazone	Metolazone	38	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	12
Topiramate	Topiramate	36	suppressed
Bupropion Xl	Bupropion Hcl	35	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	35	suppressed
Metronidazole	Metronidazole	35	28
Pregabalin	Pregabalin	35	suppressed
Irbesartan	Irbesartan	33	suppressed
Memantine Hcl	Memantine Hcl	33	suppressed
Lovastatin	Lovastatin	32	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Midodrine Hcl	Midodrine Hcl	28	13
Janumet Xr	Sitagliptin Phos/Metformin Hcl	27	suppressed
Klor-Con 10	Potassium Chloride	27	11
Methocarbamol	Methocarbamol	27	13
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	26	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	suppressed
Mupirocin	Mupirocin	26	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	26	suppressed
Prolia	Denosumab	25	16
Ramipril	Ramipril	25	suppressed
Clonazepam	Clonazepam	24	suppressed
Glipizide	Glipizide	24	suppressed
Meropenem	Meropenem	24	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	15
Folic Acid	Folic Acid	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	19
Felodipine Er	Felodipine	22	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Digoxin	Digoxin	20	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Levemir Flexpen	Insulin Detemir	20	suppressed
Divalproex Sodium	Divalproex Sodium	19	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Dexlansoprazole Dr	Dexlansoprazole	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Glipizide Er	Glipizide	18	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	18	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Cholestyramine	Cholestyramine (With Sugar)	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	16	15
Cephalexin	Cephalexin	16	14
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Galantamine Er	Galantamine Hbr	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Telmisartan	Telmisartan	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Vancomycin Hcl	Vancomycin Hcl	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Cefuroxime	Cefuroxime Axetil	15	14
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Pentoxifylline	Pentoxifylline	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	14	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Risedronate Sodium	Risedronate Sodium	14	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Lagevrio (Eua)	Molnupiravir	13	13
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Methimazole	Methimazole	13	suppressed
Novofine 32	Pen Needle, Diabetic	13	suppressed
Praluent Pen	Alirocumab	13	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	13	suppressed
Baclofen	Baclofen	12	suppressed
Clotrimazole	Clotrimazole	12	12
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Propafenone Hcl	Propafenone Hcl	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Repatha Sureclick	Evolocumab	12	suppressed
Scopolamine	Scopolamine	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Acetazolamide	Acetazolamide	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Dulera	Mometasone/Formoterol	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Modafinil	Modafinil	11	suppressed
Trimethoprim	Trimethoprim	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$21.58 · 1 records	Lilly USA, LLC	ZEPBOUND	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error